Myelodysplastic syndrome with chromosome 5 abnormalities

A nationwide survey in Japan

T. Tasaka, K. Tohyama, M. Kishimoto, K. Ohyashiki, K. Mitani, T. Hotta, A. Kanamaru, Shinichiro Okamoto, M. Karasawa, A. Kimura, M. Tomonaga, T. Uchiyama, K. Ozawa

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Chromosome 5 abnormalities, deletion of the long arm of chromosome 5 (del(5q)) or monosomy 5 (-5), arise in about 10% of myelodysplastic syndromes (MDS), either as the sole cytogenetic abnormality or as part of complicated karyotype, and has distinct clinical implications for MDS. However, the prognostic factors of MDS patients with chromosome 5 abnormalities are not determined yet. In this study, 183 Japanese MDS patients with chromosome 5 abnormalities were analyzed. Estimated incidence of del(5q) and 5q- syndrome among MDS patients was 8.4 and 1.3%, respectively. Significant shorter overall survival (OS) and leukemia-free survival (LFS) were observed in -5 patients than del(5q) patients. Among del(5q) patients, addition of monosomy 7 or complex karyotype with more than three abnormalities were significantly related to shorter OS.LFS of del(5q) patients was divided into two risk groups by international prognostic scoring system (IPSS): low/intermediate (Int)-1 and Int-2/high groups. LFS sorted by World Health Organization classification-based prognostic scoring system (WPSS) was also divided into two groups: very low/low/Int and high/very high, and WPSS was able to predict the outcome of del(5q) patients more clearly than IPSS.Together with additional cytogenetic data, WPSS might be useful for clinical decision making in MDS patients with del(5q).

Original languageEnglish
Pages (from-to)1874-1881
Number of pages8
JournalLeukemia
Volume22
Issue number10
DOIs
Publication statusPublished - 2008

Fingerprint

Chromosomes, Human, Pair 5
Myelodysplastic Syndromes
Chromosome Aberrations
Japan
Survival
Leukemia
Karyotype
Surveys and Questionnaires
Monosomy
Cytogenetics

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Tasaka, T., Tohyama, K., Kishimoto, M., Ohyashiki, K., Mitani, K., Hotta, T., ... Ozawa, K. (2008). Myelodysplastic syndrome with chromosome 5 abnormalities: A nationwide survey in Japan. Leukemia, 22(10), 1874-1881. https://doi.org/10.1038/leu.2008.199

Myelodysplastic syndrome with chromosome 5 abnormalities : A nationwide survey in Japan. / Tasaka, T.; Tohyama, K.; Kishimoto, M.; Ohyashiki, K.; Mitani, K.; Hotta, T.; Kanamaru, A.; Okamoto, Shinichiro; Karasawa, M.; Kimura, A.; Tomonaga, M.; Uchiyama, T.; Ozawa, K.

In: Leukemia, Vol. 22, No. 10, 2008, p. 1874-1881.

Research output: Contribution to journalArticle

Tasaka, T, Tohyama, K, Kishimoto, M, Ohyashiki, K, Mitani, K, Hotta, T, Kanamaru, A, Okamoto, S, Karasawa, M, Kimura, A, Tomonaga, M, Uchiyama, T & Ozawa, K 2008, 'Myelodysplastic syndrome with chromosome 5 abnormalities: A nationwide survey in Japan', Leukemia, vol. 22, no. 10, pp. 1874-1881. https://doi.org/10.1038/leu.2008.199
Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T et al. Myelodysplastic syndrome with chromosome 5 abnormalities: A nationwide survey in Japan. Leukemia. 2008;22(10):1874-1881. https://doi.org/10.1038/leu.2008.199
Tasaka, T. ; Tohyama, K. ; Kishimoto, M. ; Ohyashiki, K. ; Mitani, K. ; Hotta, T. ; Kanamaru, A. ; Okamoto, Shinichiro ; Karasawa, M. ; Kimura, A. ; Tomonaga, M. ; Uchiyama, T. ; Ozawa, K. / Myelodysplastic syndrome with chromosome 5 abnormalities : A nationwide survey in Japan. In: Leukemia. 2008 ; Vol. 22, No. 10. pp. 1874-1881.
@article{5971eb2709d6450188215843bf3847fe,
title = "Myelodysplastic syndrome with chromosome 5 abnormalities: A nationwide survey in Japan",
abstract = "Chromosome 5 abnormalities, deletion of the long arm of chromosome 5 (del(5q)) or monosomy 5 (-5), arise in about 10{\%} of myelodysplastic syndromes (MDS), either as the sole cytogenetic abnormality or as part of complicated karyotype, and has distinct clinical implications for MDS. However, the prognostic factors of MDS patients with chromosome 5 abnormalities are not determined yet. In this study, 183 Japanese MDS patients with chromosome 5 abnormalities were analyzed. Estimated incidence of del(5q) and 5q- syndrome among MDS patients was 8.4 and 1.3{\%}, respectively. Significant shorter overall survival (OS) and leukemia-free survival (LFS) were observed in -5 patients than del(5q) patients. Among del(5q) patients, addition of monosomy 7 or complex karyotype with more than three abnormalities were significantly related to shorter OS.LFS of del(5q) patients was divided into two risk groups by international prognostic scoring system (IPSS): low/intermediate (Int)-1 and Int-2/high groups. LFS sorted by World Health Organization classification-based prognostic scoring system (WPSS) was also divided into two groups: very low/low/Int and high/very high, and WPSS was able to predict the outcome of del(5q) patients more clearly than IPSS.Together with additional cytogenetic data, WPSS might be useful for clinical decision making in MDS patients with del(5q).",
author = "T. Tasaka and K. Tohyama and M. Kishimoto and K. Ohyashiki and K. Mitani and T. Hotta and A. Kanamaru and Shinichiro Okamoto and M. Karasawa and A. Kimura and M. Tomonaga and T. Uchiyama and K. Ozawa",
year = "2008",
doi = "10.1038/leu.2008.199",
language = "English",
volume = "22",
pages = "1874--1881",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Myelodysplastic syndrome with chromosome 5 abnormalities

T2 - A nationwide survey in Japan

AU - Tasaka, T.

AU - Tohyama, K.

AU - Kishimoto, M.

AU - Ohyashiki, K.

AU - Mitani, K.

AU - Hotta, T.

AU - Kanamaru, A.

AU - Okamoto, Shinichiro

AU - Karasawa, M.

AU - Kimura, A.

AU - Tomonaga, M.

AU - Uchiyama, T.

AU - Ozawa, K.

PY - 2008

Y1 - 2008

N2 - Chromosome 5 abnormalities, deletion of the long arm of chromosome 5 (del(5q)) or monosomy 5 (-5), arise in about 10% of myelodysplastic syndromes (MDS), either as the sole cytogenetic abnormality or as part of complicated karyotype, and has distinct clinical implications for MDS. However, the prognostic factors of MDS patients with chromosome 5 abnormalities are not determined yet. In this study, 183 Japanese MDS patients with chromosome 5 abnormalities were analyzed. Estimated incidence of del(5q) and 5q- syndrome among MDS patients was 8.4 and 1.3%, respectively. Significant shorter overall survival (OS) and leukemia-free survival (LFS) were observed in -5 patients than del(5q) patients. Among del(5q) patients, addition of monosomy 7 or complex karyotype with more than three abnormalities were significantly related to shorter OS.LFS of del(5q) patients was divided into two risk groups by international prognostic scoring system (IPSS): low/intermediate (Int)-1 and Int-2/high groups. LFS sorted by World Health Organization classification-based prognostic scoring system (WPSS) was also divided into two groups: very low/low/Int and high/very high, and WPSS was able to predict the outcome of del(5q) patients more clearly than IPSS.Together with additional cytogenetic data, WPSS might be useful for clinical decision making in MDS patients with del(5q).

AB - Chromosome 5 abnormalities, deletion of the long arm of chromosome 5 (del(5q)) or monosomy 5 (-5), arise in about 10% of myelodysplastic syndromes (MDS), either as the sole cytogenetic abnormality or as part of complicated karyotype, and has distinct clinical implications for MDS. However, the prognostic factors of MDS patients with chromosome 5 abnormalities are not determined yet. In this study, 183 Japanese MDS patients with chromosome 5 abnormalities were analyzed. Estimated incidence of del(5q) and 5q- syndrome among MDS patients was 8.4 and 1.3%, respectively. Significant shorter overall survival (OS) and leukemia-free survival (LFS) were observed in -5 patients than del(5q) patients. Among del(5q) patients, addition of monosomy 7 or complex karyotype with more than three abnormalities were significantly related to shorter OS.LFS of del(5q) patients was divided into two risk groups by international prognostic scoring system (IPSS): low/intermediate (Int)-1 and Int-2/high groups. LFS sorted by World Health Organization classification-based prognostic scoring system (WPSS) was also divided into two groups: very low/low/Int and high/very high, and WPSS was able to predict the outcome of del(5q) patients more clearly than IPSS.Together with additional cytogenetic data, WPSS might be useful for clinical decision making in MDS patients with del(5q).

UR - http://www.scopus.com/inward/record.url?scp=54049096659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049096659&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.199

DO - 10.1038/leu.2008.199

M3 - Article

VL - 22

SP - 1874

EP - 1881

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -